Table 3.
Cytotoxicity and anti-SARS-CoV-2 effect of CBD, CBG, and their derivatives.
| Compound | EC50 CPE [µM] | EC50 IF [µM] | CC50 [µM] |
|---|---|---|---|
| 1 (CBD) | 5.1 ± 0.99 | 8.3 ± 0.28 | 12.1 ± 1.2 |
| 8 | 21 ± 3.7 | 31 ± 1.1 | > 100 |
| 9 | 22 ± 3.0 | ~ 94a | > 100 |
| 10 | 9.0 ± 0.51 | ~ 42a | > 100 |
| 11 | 17 ± 1.5 | 33 ± 1.4 | 77 ± 2.6 |
| 12 | 11 ± 1.2 | 39 ± 1.4 | ~ 56a |
| 13 | > 12 | n.d. | 12 ± 0.28 |
| 2 (CBG) | > 11 | n.d. | ~ 11a |
| 16b | > 7.7 | n.d. | 7.7 ± 3.2 |
| 17a | > 100 | n.d. | > 100 |
| 18 | 15 ± 0.94 | > 28 | ~ 28a |
| 20 | > 100 | n.d. | > 100 |
| 21b | 12 ± 0.99 | > 100 | > 100 |
| Remdesivir | 2.8 ± 0.18 | 1.2 ± 0.03 | > 100 |
n.d. not determined, CPE cytopathic effect-based assay, IF immunofluorescence assay.
Values with bold: significant antiviral effect with no or low cytotoxicity. Values with italics: high cytotoxicity.
aApproximate value, 95% CI was too wide; therefore, standard error was not computed.